Pradžia › Ūmi bifeninė leukemija › Masčusetsas
Ūmi bifeninė leukemija klinikiniai tyrimai Masčusetsas
5 tyrimai dėl Ūmi bifeninė leukemija ieško dalyvių vietose Masčusetsas.
Miestai Masčusetsas
Oficialus tyrimo tekstas (anglų kalba)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
Renkami dalyviai2 fazė
365 Days · Visoms lytims · Atnaujinta 2026-09-25 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- ir dar 1
Renkami dalyviai3 fazė
365 Days – 25 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04726241Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius nuo 1 iki 40 · Visoms lytims · Atnaujinta 2026-03-12 · NCT05292664Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2024-12-06 · NCT05476770Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.